FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Cheruvu Pavan 2. Issuer Name and Ticker or Trading Symbol Sio Gene Therapies Inc. [ SIOX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)         (First)         (Middle)
C/O SIO GENE THERAPIES INC., 130 WEST 42ND STREET, 26TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)
12/8/2021
(Street)
NEW YORK, NY 10036
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  12/8/2021    A    37567  A $0  217993  D   
Common Stock  12/8/2021    F    14884 (1) D $1.42  203109  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units   (2) 12/8/2021    D        37567    (3)  (3) Common Stock  37567.0  $0  75133  D   

Explanation of Responses:
(1)  The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
(2)  Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
(3)  50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cheruvu Pavan
C/O SIO GENE THERAPIES INC.
130 WEST 42ND STREET, 26TH FLOOR
NEW YORK, NY 10036		 X
Chief Executive Officer

Signatures
/s/ David Nassif, Attorney-In-Fact 12/9/2021
**Signature of Reporting Person Date
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Axovant Gene Therapies Charts.
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Axovant Gene Therapies Charts.